ImmunityBio (IBRX) announced the Michael E. DeBakey Department of Veterans Affairs Medical Center in Houston has become one of the first VA hospitals in the U.S. to provide treatment with ANKTIVA. ANKTIVA, in combination with BCG, is approved by the FDA for patients with BCG-unresponsive non-muscle invasive bladder cancer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
- ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating
- ImmunityBio Reports Revenue Growth Amidst Continued Investments
- ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update
- ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment